2/3
11:31 am
sgmt
Rating for SGMT
Low
Report
Rating for SGMT
2/3
11:31 am
sgmt
Rating for SGMT
Low
Report
Rating for SGMT
2/3
08:03 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.
High
Report
Sagimet Biosciences (NASDAQ:SGMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.
2/3
08:00 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) is now covered by analysts at Guggenheim. They set a "buy" rating and a $27.00 price target on the stock.
Medium
Report
Sagimet Biosciences (NASDAQ:SGMT) is now covered by analysts at Guggenheim. They set a "buy" rating and a $27.00 price target on the stock.
2/3
08:00 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) is now covered by analysts at Guggenheim. They set a "buy" rating and a $27.00 price target on the stock.
Medium
Report
Sagimet Biosciences (NASDAQ:SGMT) is now covered by analysts at Guggenheim. They set a "buy" rating and a $27.00 price target on the stock.
2/3
07:18 am
sgmt
Sagimet Biosciences initiated with a Buy at Guggenheim
Medium
Report
Sagimet Biosciences initiated with a Buy at Guggenheim
2/3
07:18 am
sgmt
Sagimet Biosciences initiated with a Buy at Guggenheim
Medium
Report
Sagimet Biosciences initiated with a Buy at Guggenheim
1/29
07:41 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) was upgraded by analysts at Barclays PLC to a "hold" rating.
Low
Report
Sagimet Biosciences (NASDAQ:SGMT) was upgraded by analysts at Barclays PLC to a "hold" rating.
1/28
09:49 am
sgmt
Rating for SGMT
Low
Report
Rating for SGMT
1/28
09:49 am
sgmt
Rating for SGMT
Low
Report
Rating for SGMT
1/27
04:29 pm
sgmt
Sagimet Biosciences initiated with an Equal Weight at Barclays
Medium
Report
Sagimet Biosciences initiated with an Equal Weight at Barclays
1/27
04:29 pm
sgmt
Sagimet Biosciences initiated with an Equal Weight at Barclays
Medium
Report
Sagimet Biosciences initiated with an Equal Weight at Barclays
11/14
07:22 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Sagimet Biosciences (NASDAQ:SGMT) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..